NASDAQ:ARTV 17 October 2025 - 16 December 2025

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to analyst projections of multi-fold upside – underscore the high stakes and high hopes riding on AlloNK’s success. For biotech investors and observers, ARTV will be a stock to watch closely in the coming months, as upcoming trial data and FDA feedback chart the next chapter for this promising yet still speculative biotech play. 247marketnews.com za.investing.comArtiva’s stock price saw dramatic movement in the days surrounding the Fast Track announcement. On October 16, 2025, ARTV opened around $3.03 and initially traded within a tight range 247marketnews.com. However, news began to circulate about an impending announcement, and shares spiked mid-day – at one point hitting $5.754, a ~91% jump from the open 247marketnews.com. This surge was accompanied by a wave of trading volume 247marketnews.com, far above the stock’s normal activity.